Cyclic Peptides Patents (Class 530/317)
-
Publication number: 20130338075Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Inventor: Thien Nguyen
-
Patent number: 8609809Abstract: Novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are provided.Type: GrantFiled: January 19, 2010Date of Patent: December 17, 2013Assignee: Aileron Thraputics, Inc.Inventor: Huw M. Nash
-
Patent number: 8604164Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.Type: GrantFiled: February 16, 2012Date of Patent: December 10, 2013Assignee: Cubist Pharmaceuticals, Inc.Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
-
Patent number: 8603756Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.Type: GrantFiled: April 10, 2012Date of Patent: December 10, 2013Assignee: OPKO Pharmaceuticals, LLCInventors: Phillip Frost, Thomas Kodadek
-
Patent number: 8603436Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.Type: GrantFiled: March 11, 2011Date of Patent: December 10, 2013Inventor: Gerhart Graupner
-
Patent number: 8603435Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. The present invention represents a step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.Type: GrantFiled: January 12, 2009Date of Patent: December 10, 2013Assignee: STC.UNMInventors: Yubin Miao, Haixun Guo
-
Patent number: 8598316Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.Type: GrantFiled: March 26, 2010Date of Patent: December 3, 2013Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of CaliforniaInventors: Douglas Hanahan, Erkki Ruoslahti
-
Patent number: 8598313Abstract: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of FIG. 1) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.Type: GrantFiled: March 11, 2011Date of Patent: December 3, 2013Assignee: The Regents of the University of CaliforniaInventors: William H. Gerwick, Kevin Tidgewell, Frederick A. Valeriote
-
Publication number: 20130316961Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.Type: ApplicationFiled: October 24, 2011Publication date: November 28, 2013Applicants: UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Jean-Christophe Roux, Laurent Villard, Frédéric Saudou
-
Publication number: 20130317195Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: ApplicationFiled: May 23, 2013Publication date: November 28, 2013Inventor: Nicholas Chi-Kwan Ling
-
Patent number: 8592378Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.Type: GrantFiled: January 19, 2012Date of Patent: November 26, 2013Assignee: Telsar Pharma Inc.Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
-
Patent number: 8591878Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.Type: GrantFiled: February 12, 2009Date of Patent: November 26, 2013Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti SpaInventors: John A. McCauley, Nigel J. Liverton, Steven Harper, Charles J. McIntyre, Michael T. Rudd
-
Publication number: 20130310328Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: ApplicationFiled: July 31, 2013Publication date: November 21, 2013Inventor: Kunwar Shailubhai
-
Patent number: 8586545Abstract: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.Type: GrantFiled: May 20, 2010Date of Patent: November 19, 2013Assignee: Merck Patent GmbHInventors: Alfred Joncyk, Clemens Kuehn, Kerstin Seemann, Christoph Saal, Gerald Scholz, Soenke Petersen, Harald Untenecker, Michael Lange
-
Patent number: 8586744Abstract: The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.Type: GrantFiled: October 27, 2010Date of Patent: November 19, 2013Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
-
Patent number: 8580920Abstract: The present invention relates to novel peptides and to topical and food compositions comprising them. The novel peptides have applications in skin lightening and immunomodulation when applied topically and to immunomodulation and modulation of body mass when consumed in food compositions.Type: GrantFiled: November 23, 2010Date of Patent: November 12, 2013Assignee: Conopco, Inc.Inventors: Ganesh Chandramowli, Babu Rakesh Kumar Bandi
-
Patent number: 8580746Abstract: Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.Type: GrantFiled: October 2, 2009Date of Patent: November 12, 2013Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang
-
Patent number: 8580747Abstract: Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.Type: GrantFiled: November 19, 2009Date of Patent: November 12, 2013Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai
-
Publication number: 20130296256Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: ApplicationFiled: June 5, 2013Publication date: November 7, 2013Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Wei Yang, Yi-Qun Shi
-
Publication number: 20130296229Abstract: Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.Type: ApplicationFiled: November 10, 2011Publication date: November 7, 2013Applicant: SHANGHAM TECH-WELL BIOPHARMACEUTICAL CO., LTDInventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20130296529Abstract: A method for purifying a cyclic lipopepteide or a salt thereof is provided. The method comprises the steps: (1) extracting a fermentation broth containing a compound of formula I or a salt thereof, to obtain an extract 1 after filtration or centrifugation; (2) diluting or concentrating the extract 1 under vacuum to decrease the content of the organic solvent, to obtain an extract 2; (3) loading the extract 2 onto a macroporous absorption resin; (4) washing the macroporpous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution; and (5) eluting the compound of formula I off from the macroporous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution as an eluant.Type: ApplicationFiled: September 27, 2011Publication date: November 7, 2013Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Zhaoli Zhang, Shidong Liu, Zhonghao Zhuo, Xiaoming Ji
-
Patent number: 8575094Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: November 5, 2013Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20130288965Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: JOHANNES GERHARDUS MARIA BOLSCHER, ARIE VAN NIEUW AMERONGEN, ENGELMUNDUS CORNELIS IGNATIUS VEERMAN, MENNO JOHANNES OUDHOFF, WILLEM VAN'T HOF, KAMRAN NAZMI, PETRONELLA ADRIANA MARIA VAN DEN KEIJBUS
-
Patent number: 8569234Abstract: Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.Type: GrantFiled: October 7, 2005Date of Patent: October 29, 2013Assignee: Clinuvel Pharmaceuticals LimitedInventors: Michael John Kleinig, Kenneth B. Kirby, Berno I. Pettersson, Jr.
-
Patent number: 8569246Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: December 31, 2012Date of Patent: October 29, 2013Assignee: Synergy Pharamaceuticals Inc.Inventor: Kunwar Shailubhai
-
Publication number: 20130280172Abstract: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: wherein Q is a portion of a polymethine bridge: Also included are bioconjugates of the compounds of Formula I, methods of labeling biomolecules with the compounds, and methods of imaging.Type: ApplicationFiled: March 15, 2013Publication date: October 24, 2013Inventor: LI-COR, INC.
-
Publication number: 20130281657Abstract: The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.Type: ApplicationFiled: October 13, 2011Publication date: October 24, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Mark G. Saulnier, Dolatrai M. Vyas, David R. Langley, David B. Frennesson
-
Patent number: 8562948Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.Type: GrantFiled: March 31, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sandra Blaj Moore, Zelda Goodman
-
Patent number: 8563686Abstract: Conformationally constrained peptide mimetics in which a hydrogen bond interaction is replaced with a covalent hydrogen bond mimic are provided. Also provided are various methods of making these peptide mimetics.Type: GrantFiled: August 31, 2009Date of Patent: October 22, 2013Assignee: Indian Institute of ScienceInventor: Erode N. Prabhakaran
-
Publication number: 20130274205Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: ApplicationFiled: February 14, 2013Publication date: October 17, 2013Inventors: Vincent Guerlavais, Carl Elkin, Huw M. Nash, Tomi K. Sawyer, Bradford J. Graves, Eric Feyfant
-
Publication number: 20130274436Abstract: A method of radiostabilizing an oxime ligation or imine formation reaction using aniline is described.Type: ApplicationFiled: December 15, 2011Publication date: October 17, 2013Applicant: GE Healthcare LimitedInventors: Torgrim Engell, Nigel Osborn
-
Patent number: 8557765Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: May 26, 2009Date of Patent: October 15, 2013Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
-
Patent number: 8557958Abstract: The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists.Type: GrantFiled: February 1, 2013Date of Patent: October 15, 2013Assignee: Tarix Pharmaceuticals Ltd.Inventor: Richard Franklin
-
Patent number: 8551789Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.Type: GrantFiled: April 1, 2011Date of Patent: October 8, 2013Assignee: OncoMed PharmaceuticalsInventor: Austin L. Gurney
-
Patent number: 8551953Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: November 14, 2012Date of Patent: October 8, 2013Assignee: DMI Acquisition Corp.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Patent number: 8552147Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.Type: GrantFiled: December 28, 2009Date of Patent: October 8, 2013Assignee: Tel Hashomer Medical Research, Infrastructure and Services Ltd.Inventor: Amir Zlotkin
-
Publication number: 20130261286Abstract: The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin) represented by the following formula 1, which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process:Type: ApplicationFiled: January 12, 2011Publication date: October 3, 2013Applicant: CKD BIO CORP.Inventors: Heui-Il Kang, Yun-Beom Ham, Su-Hyun Kyong, Heung-Mo Kang, Tae-Hee Han, Doo-Jin Kang
-
Publication number: 20130259804Abstract: The present invention relates to improved radiotracer imaging agent compositions, which comprises 18F-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.Type: ApplicationFiled: December 9, 2011Publication date: October 3, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Torgrim Engell, Julian Grigg, Dimtrios Mantzilas
-
Patent number: 8546531Abstract: Multifunctional probes are synthesized in a single step using peptide scaffold-based multifunctional single-attachment-point reagents. To obtain multifunctional probes using the methods of the invention, a substrate (e.g., a nanoparticle, polymer, antibody, protein, low molecular weight compound, drug, etc.) is reacted with a multifunctional single-attachment-point (MSAP) reagent. The MSAP reagents can include three components: (i) a peptide scaffold, (ii) a single chemically reactive group on the peptide scaffold for reaction of the MSAP with a substrate having a complementary reactive group, and (iii) multiple functional groups on the peptide scaffold. The peptide scaffold can include any number of residues; however, for ease of synthesis and reproducibility in clinical trials, it is preferred to limit the residues in the peptide to 20 or less.Type: GrantFiled: July 15, 2009Date of Patent: October 1, 2013Assignee: The General Hospital CorporationInventors: Lee Josephson, Elisabeth Garanger
-
Patent number: 8546526Abstract: The present invention is related to new peptide antagonists of ?v?3 receptor, designed on the basis of the crystal structure of integrin ?v?3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the ?v?3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for ?v?3-targeted therapy and imaging.Type: GrantFiled: October 9, 2006Date of Patent: October 1, 2013Assignee: Advanced Accelerator ApplicationsInventors: Annarita del Gatto, Laura Zaccaro, Carlo Pedone, Michele Saviano
-
Patent number: 8541545Abstract: Compositions and methods are disclosed for a non-naturally occurring melanocortin ligand comprised of a melanocortin analog coupled to a degradation-resistant C-terminal extension and, optionally, an N-terminal extension, to produce a stable melanocortin ligand having diminished or abolished cardiovascular activity while retaining desired melanocortin regulatory activity.Type: GrantFiled: August 30, 2010Date of Patent: September 24, 2013Assignee: Tensive Controls Inc.Inventor: Kenneth A. Gruber
-
Patent number: 8536114Abstract: Disclosed herein are compounds of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, and their use as pharmaceuticals.Type: GrantFiled: December 30, 2009Date of Patent: September 17, 2013Assignee: Scynexis, Inc.Inventors: Keqiang Li, David Renwick Houck, Cyprian Okwara Ogbu, Michael Robert Peel, Andrew William Scribner
-
Publication number: 20130237685Abstract: Provided is a macromolecule comprising two or more functionalized bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the functionalized bis-peptides are covalently attached to one or more functionalized bis-peptides to form linear strings of functionalized bis-peptides, macrocycles of functionalized bis-peptides, three-dimensional networks of functionalized bis-peptides, and combinations of any of these. Also provided is a macromolecule comprising two or more bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the bis-peptides comprise non-functionalized bis-peptides, functionalized bis-peptides or a combination of both functionalized and non-functionalized bis-peptides. In some embodiments, the bis-peptides are covalently attached to one or more bis-peptides to form linear strings of bis-peptides, macrocycles of bis-peptides, three-dimensional networks of bis-peptides, and combinations of any of these.Type: ApplicationFiled: November 16, 2011Publication date: September 12, 2013Applicants: University Of Pittsburgh - Of The Commonwealth System Of Higher Education, Temple University - Of The Commonwealth System Of Higher EducationInventors: Christian E. Schafmeister, Matthew F. Parker
-
Publication number: 20130237473Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: May 3, 2013Publication date: September 12, 2013Applicant: AstraZeneca ABInventors: John H. Dodd, Yi-Qun Shi, Wei Yang
-
Publication number: 20130224237Abstract: Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases.Type: ApplicationFiled: July 20, 2011Publication date: August 29, 2013Applicant: UNIVERSITY OF MIAMIInventor: Eli Gilboa
-
Publication number: 20130224835Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: ApplicationFiled: April 2, 2013Publication date: August 29, 2013Applicant: HAMMERSMITH IMANET LIMITEDInventor: HAMMERSMITH IMANET LIMITED
-
Publication number: 20130225482Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.Type: ApplicationFiled: November 10, 2011Publication date: August 29, 2013Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20130224231Abstract: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention.Type: ApplicationFiled: January 27, 2012Publication date: August 29, 2013Applicant: Inimex Pharmaceuticals, Inc.Inventors: Oreola Donini, Annett Rozek, Shannon Wayne Lentz
-
Patent number: 8518871Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: October 5, 2011Date of Patent: August 27, 2013Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Patent number: 8513185Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: GrantFiled: October 13, 2010Date of Patent: August 20, 2013Inventor: Alexander B. Sigalov